AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2015
Apr 28, 2015
31289_dirs_2015-04-27_a953572f-6678-45f7-84af-7d2fe3de0883.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2015-04-24
Reporting Person: Davis Todd C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-04-24 | Common Stock | A | 925.0 | $0.0 | Acquired | 35278 | Direct |
| 2015-04-24 | Common Stock | A | 501.0 | $0.0 | Acquired | 35779 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-04-24 | Non-Qualified Stock Option (right to buy) | $89.75 | A | 2754.0 | Acquired | 2025-04-24 | Common Stock (2754) | Direct |
Footnotes
F1: Acquired by a grant of the Board of Directors of the Company at their annual meeting on April 24, 2015. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: Immediately vested restricted shares issued in lieu of annual cash retainer
F3: Acquired by a grant of the Board of Directors of the Company at their annual meeting on April 24, 2015. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.